University of Dundee

School of Research

Short Code: 
SoR

MMV Project of the Year Award for Dundee researchers

Researchers from the Drug Discovery Unit have been awarded the “Project of the Year 2018” from Medicines for Malaria Venture (MMV) for their discovery work on potential new drugs for malaria.

The annual award goes to the scientific partners involved in that year’s most exciting project from the MMV portfolio. MMV is the world’s leading product development partnership (PDP) for discovering and developing new effective and affordable medicines to treat malaria.

Protein discovery could pave way for parasite research

A team of scientists at the School of Life Sciences have identified a protein that makes random decisions to allow parasites to survive in their human hosts. They have been able to identify a complex that allows genes to switch on and off randomly, changing cell surface characteristics and allowing escape from the defences of the host’s immune system. This behaviour is present in genes within parasites known as trypanosomes, and also in the parasite that causes malaria, which claims hundreds of thousands of lives every year.

The Strange Case of AMPK and Cancer: Dr Jekyll or Mr Hyde?

Prof. Grahame Hardie and two of his co-workers, Diana Vara-Ciruelos and Fiona Russell, have published a review in the journal Open Biology with a title inspired by the classic novella by the Scottish author Robert Louis Stevenson. Their article discusses the controversial role in cancer of AMP-activated protein kinase (AMPK), which was first defined and named by Prof. Hardie at the University of Dundee in the late 1980s.

University of Dundee and Eisai enter partnership for cancer drug discovery using targeted protein degradation

The University of Dundee has announced a new partnership with Eisai, one of the world’s leading research-based pharmaceutical companies, aiming to create innovative new drugs for the cancer field. The collaboration combines the world-leading PROTACs expertise and technology of Professor Alessio Ciulli from the Division of Biological Chemistry and Drug Discovery in the School with Eisai’s discovery research and clinical development experiences in oncology.

Major announcements from OME collaborative projects

This week has seen two major announcements made on projects that Open Microscopy Environment (OME), led by Professor Jason Swedlow in the School, have collaborated on:

1. Euro-BioImaging European Research Infrastructure Consortia

The UK will be joining the Euro-BioImaging European Research Infrastructure Consortia, hosted in Finland, as a founder member. OME has participated in Euro-BioImaging since its inception and has led its efforts to build public resources for imaging data.

DDU partners with Bukwang Pharmaceutical Company to tackle new drug treatment for Parkinson’s disease

The Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson’s disease. This announcement builds upon existing drug discovery partnerships the DDU has with Takeda and GSK.

Parkinson’s disease is the second most common neurological disorder, after Alzheimer’s disease, affecting around two people in every 1000 across the population. There are around 6.1 million people worldwide and 120,000 people in the UK living with the condition.

SLS PhD students selected to participate in Roche Continents 2019

Two PhD students in the School have been selected to join Europe’s finest University students in creative and intellectual collaboration at Roche Continents 2019.

The highly prestigious Roche Continents - a full week of interdisciplinary challenges and inspiration – selects only 100 students from the sciences and arts at European Universities to attend. Tom Snelling from Philip Cohen's Lab (MRC-PPU) and Margarita Kalamara from Nicola Stanley-Wall’s Lab (Molecular Microbiology) are two of those who will take part in the week of activities in Salzburg in August.

Pages